Pharmaceutical News

RSS

B. Braun Medical announces agreement with HealthTrust to provide pain management products

B. Braun Medical Inc. (B. Braun) has announced an expanded agreement with HealthTrust Purchasing Group (HealthTrust) to provide pain management products to HealthTrust's membership.

From B. Braun Melsungen AG 12 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Z-Medica launches QuikClot Trauma Pad

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced the availability of the QuikClot® Trauma Pad™ hemostatic dressing, on display at booth #1721 at the American College of Surgeons 95th Annual Clinical Congress. The new QuikClot Trauma Pad’s 12 x 12 inch size makes it well-suited to control bleeding from large traumatic wounds.

From Medica Corporation 12 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Communications technology for students and employees to manage their healthcare relationships

Allviant Corporation today announced the launch of its CarePass™ pilot program with Arizona State University to add another tool to the university’s health and wellness communications and services while empowering its employees and students with tools to manage their healthcare relationships.

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.

12 Oct 2009

Pieris reports its progress in the development of PRS-050

Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

12 Oct 2009

PPA bus tour to raise awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Iowa, Southern Illinois, and Southern Indiana throughout the week of October 12 -- 16th at various cities in order to help uninsured and financially-struggling Midwesterners access information on programs that provide prescription medicines for free or nearly free.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

Arch Pharmalabs collaborates with Orochem Technologies to manufacture an API in India

Arch Pharmalabs, Ltd., a leading provider of small molecule process R&D and full life-cycle custom synthesis and manufacturing services, announced today it has entered into a strategic partnership with Orochem Technologies, Inc., to manufacture a U.S. innovator’s active pharmaceutical ingredient (API) in late-stage clinical development using Simulated Moving Bed (SMB) technology.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Wal-Mart Stores, Inc. announced today that more than 4,000 Walmart and Sam's Club pharmacies nationwide will address the national shortage of Tamiflu® oral suspension by converting the capsule to liquid form.

12 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

State governments start swine flu vaccine campaign

Questions, answers and reactions emerge as various states and counties distribute H1N1 flu vaccines.

9 Oct 2009

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

9 Oct 2009

St. Petersburg City Council partners with American Lung Association for "Faces of Influenza" campaign

Mayor Rick Baker and members of St. Petersburg City Council are partnering with the American Lung Association in Florida Gulfcoast area on its Faces of Influenza educational initiative to kick off the 2009-2010 influenza season in Tampa/St. Petersburg.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

Sanofi-aventis Canada welcomes the Quebec Biopharmaceutical Strategy and sees a strong link with its new corporate strategy.

9 Oct 2009

Pharmaceutical News

B. Braun Medical announces agreement with HealthTrust to provide pain management products

QRxPharma signs contractual agreement with Patheon

Z-Medica launches QuikClot Trauma Pad

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

Communications technology for students and employees to manage their healthcare relationships

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Pieris reports its progress in the development of PRS-050

PPA bus tour to raise awareness of patient assistance programs

FDA approves Berinert for the treatment of hereditary angioedema

Arch Pharmalabs collaborates with Orochem Technologies to manufacture an API in India

Presentations on efficacy of interferon to combat influenza

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

State governments start swine flu vaccine campaign

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

St. Petersburg City Council partners with American Lung Association for "Faces of Influenza" campaign

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News